Neogen Corp
$
58.61
0 (0%)
On watch
| Volume: | 118,593 | Avg Vol (1m): | 201,020 |
| Market Cap $: | 3.05 Bil | Enterprise Value $: | 2.81 Bil |
| P/E (TTM): | 49.66 | P/B: | 4.97 |
| Earnings Power Value | 15.43 |
| Net Current Asset Value | 7.05 |
| Tangible Book | 8.51 |
| Projected FCF | 17.82 |
| Median P/S Value | 47.91 |
| Graham Number | 15.03 |
| Peter Lynch Value | 12.51 |
| DCF (FCF Based) | 21.31 |
| DCF (Earnings Based) | 22.61 |
1Y (-%)
Add to portfolio
Email alerts
Stock PDF
RSS
Website
Filings
Download Excel
Batch Download
Manual of Stocks™ Web
Manual of Stocks™
Manual of Stocks™ Web
Manual of Stocks™
Financial Strength : 10/10
GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
| Current | vs industry | vs history | |
|---|---|---|---|
| Cash-to-Debt | No Debt |
Cash-To-Debt ranked
higher than
96.93%
of
261
companies
in the
Diagnostics & Research
industry.
Industry Max: 32990, Med: 3.52, Min: 0.01
NEOG:
No Debt
Ranked among companies with meaningful Cash-To-Debt only.
|
Cash-To-Debt range over the past 10 years
Min: 0.15, Med: 10000, Max: 10000
Current: 10000
|
| Equity-to-Asset | 0.92 |
Equity-to-Asset ranked
higher than
90.79%
of
239
companies
in the
Diagnostics & Research
industry.
Industry Max: 0.97, Med: 0.61, Min: -2.81
NEOG:
0.92
Ranked among companies with meaningful Equity-to-Asset only.
|
Equity-to-Asset range over the past 10 years
Min: 0.72, Med: 0.88, Max: 0.93
Current: 0.92
|
| Interest Coverage | No Debt |
Interest Coverage ranked
higher than
96.93%
of
163
companies
in the
Diagnostics & Research
industry.
Industry Max: 15605.52, Med: 76.01, Min: 0.54
NEOG:
No Debt
Ranked among companies with meaningful Interest Coverage only.
| N/A |
| Piotroski F-Score | 5 |
0
1
2
3
4
5
6
7
8
9
| |
| Altman Z-Score | 37.50 |
DISTRESS
GREY
SAFE
| |
| Beneish M-Score | -2.39 |
Not Manipulator
Manipulator
| |
| WACC vs ROIC % |
ROIC 16.33%
WACC 8.58%
| ||
Profitability & Growth : 8/10
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
| Current | vs industry | vs history | |
|---|---|---|---|
| Operating Margin % | 16.61 |
Operating Margin ranked
higher than
86.78%
of
242
companies
in the
Diagnostics & Research
industry.
Industry Max: 53.36, Med: -0.59, Min: -70300
NEOG:
16.61
Ranked among companies with meaningful Operating Margin only.
|
Operating Margin range over the past 10 years
Min: 16.61, Med: 18.15, Max: 20.75
Current: 16.61
|
| Net Margin % | 14.85 |
Net Margin ranked
higher than
87.14%
of
241
companies
in the
Diagnostics & Research
industry.
Industry Max: 41.13, Med: -2.48, Min: -119600
NEOG:
14.85
Ranked among companies with meaningful Net Margin only.
|
Net Margin range over the past 10 years
Min: 11.38, Med: 12.17, Max: 15.7
Current: 14.85
|
| ROE % | 10.65 |
ROE ranked
higher than
74.38%
of
242
companies
in the
Diagnostics & Research
industry.
Industry Max: 61.7, Med: -6.75, Min: -12038.19
NEOG:
10.65
Ranked among companies with meaningful ROE only.
|
ROE range over the past 10 years
Min: 9.68, Med: 11.23, Max: 13.38
Current: 10.65
|
| ROA % | 9.71 |
ROA ranked
higher than
85.11%
of
262
companies
in the
Diagnostics & Research
industry.
Industry Max: 1174.65, Med: -4.54, Min: -1248.4
NEOG:
9.71
Ranked among companies with meaningful ROA only.
|
ROA range over the past 10 years
Min: 8.68, Med: 9.79, Max: 11.42
Current: 9.71
|
| ROC (Joel Greenblatt) % | 33.78 |
ROC (Joel Greenblatt) ranked
higher than
79.54%
of
259
companies
in the
Diagnostics & Research
industry.
Industry Max: 17601.65, Med: -9.57, Min: -3842027.78
NEOG:
33.78
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
|
ROC (Joel Greenblatt) range over the past 10 years
Min: 33.35, Med: 39.04, Max: 52.57
Current: 33.78
|
| 3-Year Total Revenue Growth Rate | 12.40 |
3-Year Revenue Growth Rate ranked
higher than
67.03%
of
182
companies
in the
Diagnostics & Research
industry.
Industry Max: 371, Med: 4.8, Min: -100
NEOG:
10.8
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
|
3-Year Revenue Growth Rate range over the past 10 years
Min: -15.3, Med: 13.4, Max: 26.4
Current: 10.8
|
| 3-Year Total EBITDA Growth Rate | 11.00 |
3-Year EBITDA Growth Rate ranked
higher than
58.43%
of
178
companies
in the
Diagnostics & Research
industry.
Industry Max: 141.7, Med: 10.1, Min: -340.1
NEOG:
9.4
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
|
3-Year EBITDA Growth Rate range over the past 10 years
Min: 0, Med: 15.5, Max: 40.1
Current: 9.4
|
| 3-Year EPS w/o NRI Growth Rate | 21.50 |
3-Year EPS w/o NRI Growth Rate ranked
higher than
57.67%
of
163
companies
in the
Diagnostics & Research
industry.
Industry Max: 138.7, Med: 10.1, Min: -301
NEOG:
21.5
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
|
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: 0, Med: 15.1, Max: 31.9
Current: 21.5
|
» NEOG's 30-Y Financials
Financials (Next Earnings Date: 2019-07-18)
Guru Trades Click for details
Guru Trades in
SEC Filings
Gurus Latest Trades with NAS:NEOG
» Interactive Chart
Peter Lynch Chart
Business Description
| Industry | Medical Diagnostics & Research » Diagnostics & Research   NAICS : 325412   SIC : 2835 |
| Compare | NAS:QDEL NAS:GHDX SHSE:603658 NAS:MYGN SZSE:300676 BSP:DASA3 NAS:MEDP NAS:NEO SHSE:603882 NAS:BEAT NYSE:NVTA SZSE:300463 SZSE:300244 SZSE:300482 BSP:FLRY3 TSE:4544 SZSE:300406 OSTO:SECT B NAS:SYNH NAS:VREX |
| Traded in other countries | NG2.Germany |
| Address | 620 Lesher Place, Lansing, MI, USA, 48912 |
| Neogen Corp develops and markets a range of products related to food and animal safety. Its food safety segment sells diagnostic test kits to food producers and processors that detect harmful substances in human food and animal feed, like foodborne pathogens, natural toxins, food allergens, and pesticide residues. Most of these tests are disposable products. The animal safety segment manufactures pharmaceuticals, vaccines, veterinary instruments, rodenticides, and insecticides for the animal safety market. These products are largely used by the veterinary and agricultural industries. The animal safety segment generates over half of Neogen's revenue. The firm's customers are primarily located in the United States. | |
Ratios
| Current | vs industry | vs history | |
|---|---|---|---|
| PE Ratio (TTM) | 49.66 |
PE Ratio ranked
lower than
78.76%
of
113
companies
in the
Diagnostics & Research
industry.
Industry Max: 1345, Med: 35, Min: 0.33
NEOG:
49.66
Ranked among companies with meaningful PE Ratio only.
|
PE Ratio range over the past 10 years
Min: 21, Med: 49.16, Max: 75.98
Current: 49.66
|
| Forward PE Ratio | 48.78 |
Forward P/E ranked
lower than
92.50%
of
40
companies
in the
Diagnostics & Research
industry.
Industry Max: 78.74, Med: 9999, Min: 11.64
NEOG:
48.78
Ranked among companies with meaningful Forward P/E only.
| N/A |
| PE Ratio without NRI | 49.66 |
PE without NRI ranked
lower than
78.76%
of
113
companies
in the
Diagnostics & Research
industry.
Industry Max: 1345, Med: 35.56, Min: 0.34
NEOG:
49.66
Ranked among companies with meaningful PE without NRI only.
|
PE without NRI range over the past 10 years
Min: 21, Med: 49.16, Max: 75.98
Current: 49.66
|
| Price-to-Owner-Earnings | 60.79 |
Price-to-Owner-Earnings ranked
lower than
77.63%
of
76
companies
in the
Diagnostics & Research
industry.
Industry Max: 1523.53, Med: 36.75, Min: 4.91
NEOG:
60.79
Ranked among companies with meaningful Price-to-Owner-Earnings only.
|
Price-to-Owner-Earnings range over the past 10 years
Min: 22.88, Med: 64.69, Max: 131.04
Current: 60.79
|
| PB Ratio | 4.97 |
PB Ratio ranked
lower than
65.31%
of
245
companies
in the
Diagnostics & Research
industry.
Industry Max: 270, Med: 4.02, Min: 0.15
NEOG:
4.97
Ranked among companies with meaningful PB Ratio only.
|
PB Ratio range over the past 10 years
Min: 2.24, Med: 4.93, Max: 8.63
Current: 4.97
|
| PS Ratio | 7.38 |
PS Ratio ranked
lower than
68.70%
of
230
companies
in the
Diagnostics & Research
industry.
Industry Max: 6350, Med: 3.81, Min: 0.07
NEOG:
7.38
Ranked among companies with meaningful PS Ratio only.
|
PS Ratio range over the past 10 years
Min: 2.49, Med: 6.05, Max: 12.4
Current: 7.38
|
| Price-to-Free-Cash-Flow | 62.97 |
Price-to-Free-Cash-Flow ranked
lower than
82.50%
of
80
companies
in the
Diagnostics & Research
industry.
Industry Max: 1356.19, Med: 29.22, Min: 0.35
NEOG:
62.97
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
|
Price-to-Free-Cash-Flow range over the past 10 years
Min: 21.27, Med: 66.38, Max: 428.7
Current: 62.97
|
| Price-to-Operating-Cash-Flow | 47.04 |
Price-to-Operating-Cash-Flow ranked
lower than
84.54%
of
97
companies
in the
Diagnostics & Research
industry.
Industry Max: 1739.7, Med: 19.94, Min: 0.35
NEOG:
47.04
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
|
Price-to-Operating-Cash-Flow range over the past 10 years
Min: 18.51, Med: 46.04, Max: 76.04
Current: 47.04
|
| EV-to-EBIT | 40.55 |
EV-to-EBIT ranked
lower than
88.98%
of
118
companies
in the
Diagnostics & Research
industry.
Industry Max: 341.21, Med: 25.06, Min: 5.74
NEOG:
40.55
Ranked among companies with meaningful EV-to-EBIT only.
|
EV-to-EBIT range over the past 10 years
Min: 13.8, Med: 30.9, Max: 69.3
Current: 40.55
|
| EV-to-EBITDA | 32.43 |
EV-to-EBITDA ranked
lower than
87.12%
of
132
companies
in the
Diagnostics & Research
industry.
Industry Max: 486.47, Med: 20.75, Min: 3.94
NEOG:
32.43
Ranked among companies with meaningful EV-to-EBITDA only.
|
EV-to-EBITDA range over the past 10 years
Min: 11.5, Med: 25.8, Max: 55.6
Current: 32.43
|
| EV-to-Revenue | 6.74 |
EV-to-Revenue ranked
lower than
72.31%
of
242
companies
in the
Diagnostics & Research
industry.
Industry Max: 19679, Med: 4.24, Min: 0.09
NEOG:
6.74
Ranked among companies with meaningful EV-to-Revenue only.
|
EV-to-Revenue range over the past 10 years
Min: 2.4, Med: 5.7, Max: 11.9
Current: 6.74
|
| PEG Ratio | 4.30 |
PEG Ratio ranked
lower than
66.67%
of
48
companies
in the
Diagnostics & Research
industry.
Industry Max: 128.13, Med: 3.26, Min: 0.32
NEOG:
4.3
Ranked among companies with meaningful PEG Ratio only.
|
PEG Ratio range over the past 10 years
Min: 1, Med: 3.74, Max: 6.58
Current: 4.3
|
| Shiller PE Ratio | 80.29 |
Shiller PE Ratio ranked
lower than
82.05%
of
39
companies
in the
Diagnostics & Research
industry.
Industry Max: 459.08, Med: 52.49, Min: 10.19
NEOG:
80.29
Ranked among companies with meaningful Shiller PE Ratio only.
|
Shiller PE Ratio range over the past 10 years
Min: 37.06, Med: 79.79, Max: 139.86
Current: 80.29
|
| Current Ratio | 12.33 |
Current Ratio ranked
higher than
88.40%
of
250
companies
in the
Diagnostics & Research
industry.
Industry Max: 97.84, Med: 2.58, Min: 0.02
NEOG:
12.33
Ranked among companies with meaningful Current Ratio only.
|
Current Ratio range over the past 10 years
Min: 3.16, Med: 6.73, Max: 14.54
Current: 12.33
|
| Quick Ratio | 9.86 |
Quick Ratio ranked
higher than
86.80%
of
250
companies
in the
Diagnostics & Research
industry.
Industry Max: 97.84, Med: 2.14, Min: 0.02
NEOG:
9.86
Ranked among companies with meaningful Quick Ratio only.
|
Quick Ratio range over the past 10 years
Min: 1.55, Med: 4.59, Max: 10.77
Current: 9.86
|
| Days Inventory | 129.84 |
Days Inventory ranked
lower than
72.55%
of
204
companies
in the
Diagnostics & Research
industry.
Industry Max: 917.88, Med: 79.76, Min: 0.37
NEOG:
129.84
Ranked among companies with meaningful Days Inventory only.
|
Days Inventory range over the past 10 years
Min: 125.82, Med: 132.89, Max: 182.11
Current: 129.84
|
| Days Sales Outstanding | 70.06 |
Days Sales Outstanding ranked
lower than
54.90%
of
204
companies
in the
Diagnostics & Research
industry.
Industry Max: 521.64, Med: 67.51, Min: 1
NEOG:
70.06
Ranked among companies with meaningful Days Sales Outstanding only.
|
Days Sales Outstanding range over the past 10 years
Min: 60.52, Med: 71.51, Max: 76.86
Current: 70.06
|
| Days Payable | 31.02 |
Days Payable ranked
lower than
80.21%
of
187
companies
in the
Diagnostics & Research
industry.
Industry Max: 981.81, Med: 63.34, Min: 1
NEOG:
31.02
Ranked among companies with meaningful Days Payable only.
|
Days Payable range over the past 10 years
Min: 24.07, Med: 35.29, Max: 42.87
Current: 31.02
|
Dividend & Buy Back
| Current | vs industry | vs history | |
|---|---|---|---|
| 3-Year Share Buyback Rate | -1.50 |
3-Year Share Buyback Rate ranked
higher than
76.67%
of
180
companies
in the
Diagnostics & Research
industry.
Industry Max: 3.4, Med: -7.9, Min: -1732.6
NEOG:
-1.5
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
|
3-Year Share Buyback Rate range over the past 10 years
Min: -21.4, Med: -2.4, Max: 2.1
Current: -1.5
|
Valuation & Return
| Current | vs industry | vs history | |
|---|---|---|---|
| Price-to-Tangible-Book | 6.89 |
Price-to-Tangible-Book ranked
lower than
63.29%
of
207
companies
in the
Diagnostics & Research
industry.
Industry Max: 272.36, Med: 6.46, Min: 0.21
NEOG:
6.89
Ranked among companies with meaningful Price-to-Tangible-Book only.
|
Price-to-Tangible-Book range over the past 10 years
Min: 1.49, Med: 4.97, Max: 11.86
Current: 6.89
|
| Price-to-Projected-FCF | 3.29 |
Price-to-Intrinsic-Value-Projected-FCF ranked
lower than
65.33%
of
75
companies
in the
Diagnostics & Research
industry.
Industry Max: 449, Med: 2.41, Min: 0.47
NEOG:
3.29
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
|
Price-to-Intrinsic-Value-Projected-FCF range over the past 10 years
Min: 0.96, Med: 2.62, Max: 10.75
Current: 3.29
|
| Price-to-DCF (Earnings Based) | 2.59 |
Price-to-Intrinsic-Value-DCF (Earnings Based) ranked
lower than
64.71%
of
17
companies
in the
Diagnostics & Research
industry.
Industry Max: 6.59, Med: 1.86, Min: 0.72
NEOG:
2.59
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
|
Price-to-Intrinsic-Value-DCF (Earnings Based) range over the past 10 years
Min: 1.23, Med: 2.15, Max: 3.89
Current: 2.59
|
| Price-to-Median-PS-Value | 1.22 |
Price-to-Median-PS-Value ranked
lower than
70.98%
of
193
companies
in the
Diagnostics & Research
industry.
Industry Max: 7.22, Med: 1.01, Min: 0.01
NEOG:
1.22
Ranked among companies with meaningful Price-to-Median-PS-Value only.
|
Price-to-Median-PS-Value range over the past 10 years
Min: 0.14, Med: 0.5, Max: 1.99
Current: 1.22
|
| Price-to-Peter-Lynch-Fair-Value | 4.69 |
Price-to-Peter-Lynch-Fair-Value ranked
lower than
90.00%
of
30
companies
in the
Diagnostics & Research
industry.
Industry Max: 15.31, Med: 2.01, Min: 0.83
NEOG:
4.69
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
|
Price-to-Peter-Lynch-Fair-Value range over the past 10 years
Min: 0.33, Med: 1.99, Max: 6.37
Current: 4.69
|
| Price-to-Graham-Number | 3.90 |
Price-to-Graham-Number ranked
lower than
71.05%
of
76
companies
in the
Diagnostics & Research
industry.
Industry Max: 49.42, Med: 3.98, Min: 0.39
NEOG:
3.9
Ranked among companies with meaningful Price-to-Graham-Number only.
|
Price-to-Graham-Number range over the past 10 years
Min: 0.89, Med: 2.88, Max: 6.23
Current: 3.9
|
| Earnings Yield (Joel Greenblatt) % | 2.46 |
Earnings Yield (Greenblatt) ranked
higher than
60.38%
of
265
companies
in the
Diagnostics & Research
industry.
Industry Max: 17.42, Med: -0.98, Min: -1428.57
NEOG:
2.46
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
|
Earnings Yield (Greenblatt) range over the past 10 years
Min: 1.4, Med: 3.2, Max: 7.3
Current: 2.46
|
| Forward Rate of Return (Yacktman) % | 11.76 |
Forward Rate of Return ranked
higher than
62.86%
of
70
companies
in the
Diagnostics & Research
industry.
Industry Max: 7802.99, Med: 8.45, Min: -35.9
NEOG:
11.76
Ranked among companies with meaningful Forward Rate of Return only.
|
Forward Rate of Return range over the past 10 years
Min: 11.7, Med: 15.8, Max: 21.9
Current: 11.76
|
More Statistics
| Revenue (TTM) (Mil) $ | 416.87 |
| EPS (TTM) $ | 1.18 |
| Beta | 1.03 |
| Volatility % | 39.81 |
| 52-Week Range $ | 50.6 - 97.38 |
| Shares Outstanding (Mil) | 52.12 |
Analyst Estimate
Piotroski F-Score Details
| Piotroski F-Score | 5 |
| Positive ROA | Y |
| Positive CFROA | Y |
| Higher ROA yoy | N |
| CFROA > ROA | Y |
| Lower Leverage yoy | Y |
| Higher Current Ratio yoy | Y |
| Less Shares Outstanding yoy | N |
| Higher Gross Margin yoy | N |
| Higher Asset Turnover yoy | N |